Deven Choksey's research report on Granules India
Granules’ revenue came in at INR 11,974 Mn., up 1.8% YoY (+5.3% QoQ), below our estimates (-9.6%) impacted by weaker growth traction in API and PFI segments. EBITDA stood at INR 2,524 Mn., down 1.3% YoY (+9.6% QoQ), sharply below our estimates (- 12.0%), led by higher operating expenses. Adjusted Net profit stood at INR 1,213 Mn., down 6.5% YoY (+3.1% QoQ), sharply below our estimates (-25.1%), led by subdued growth, poor operational performance, higher depreciation expense and lower other income. We have revised our FY26E/FY27E EPS estimates by -6.0%/-12.4%, respectively, as we bake in weaker H1FY26 led by regulatory risk from the FDA, more gradual ramp up of margins led by weak operating leverage and lower other income. We believe that long-term growth will be driven by scaling up complex generic's portfolio, and its Genome Valley facility.
Outlook
We value Granules at 20.5x FY27E EPS, implying a target price of INR 612. We maintain our “BUY” rating on the stock.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
